Abstract: Gestational trophoblastic neoplasms (GTN) are highly curable tumors, with an overall patient survival of 90%, due to the individualized chemotherapy. However, chemotherapy regimens vary between different treatment centers and the comparable benefits and risks of these different regimens are unclear. Here, we reported a case of GTN with oculocutaneous albinism (OCA) is resistant to fluorouracil (5-FU), extremely sensitive to actinomycin D (Act-D) with severe hand-foot skin reaction (HFSR). We hypothesized that the known, or unknown, gene mutations might be correlated with drug resistance, supersensitivity and severe drug side effects in OCA patients. Thus, we considered that OCA related genes influence some drug sensitivity and that the absence of melanin likely contributes to some drug resistance. It is important to assess the OCA related gene mutations locus of drug sensitivity, and resistance in OCA patients in future research.
Introduction
Hand-foot skin reaction (HFSR) is the most common and severe adverse reaction after targeted therapy with multitargeted kinase inhibitors (MKIs). It has been reported that the incidence of HFSR with MKIs is as high as 51.4%. Skin lesions of HFSR have shown a series of symptoms that may affect the skin of the hands and/or feet including; burning, erythema, swelling, blister and chapped. According to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0, the severity of HFSR can be divided into the following degrees: degree I, mild skin change or dermatitis (eg, erythema), without pain; degree II, skin change (eg, blister, hemorrhage, edema) or pain, without affecting daily life; degree III, ulcerative dermatitis caused skin burst with pain, seriously impacting daily life. 1 Studies have shown that the incidence of HFSR is not related to age, chemotherapy drugs, baseline neuropathy or rash; however, that may be related to the expression of tumor necrosis factor-alpha (TNF-alpha). 2 Oculocutaneous albinism (OCA) is an autosomal recessive disorder. The main clinical manifestation is the deficiency of pigment in all parts of the body. The related clinical symptoms cannot be treated so far. It also seriously affects the patients' physical and mental health. There are no reports concerning potential risks for patients who receive related treatments when they are affected with other diseases.
Act-D is a relatively well-tolerated drug with minimal side effects, even in pediatric patients with Wilms tumor. 3 Previous pharmacokinetic studies demonstrated submit your manuscript | www.dovepress.com
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Case report
A 26-year-old G2P1 female patient with OCA ( Figure 1 No HFS or pigmentation developed in this patient. After the 3 courses of 5-FU chemotherapy, the level of β-HCG gradually decreased which indicated potential resistance to 5-FU by the end of the 4 courses. From the 5 courses of chemotherapy, the patient was switched to Act-D chemotherapy (8-10 µg/kg × 8 d), which was also repeated every 2 weeks. After 2 courses of the Act-D chemotherapy, the β-HCG returned to normal levels ( Figure 2 ). On the fifth day of the 2 courses of Act-D chemotherapy, the terminal skin of hand and foot started to show burning sensation and the dry flushing. Three days after finishing of the 2 courses of Act-D chemotherapy, the skin of the hand and foot was slightly swollen, and also blister, erythema, exudate, and pain were observed ( Figure 3A ). The skin symptoms were improved with urea ointment by local topical application. The patient received the first additional course of Act-D chemotherapy to reduce relapse as scheduled. Only 3 days after finishing of the treatment, the patient suffered from fever and severe HFSR (manifestation of ulcerative dermatitis) ( Figure 3B ). As shown in the histopathological analysis, a great number of neutrophils, fibrinoid degeneration of the inferior vascular wall, infiltration of perivascular lymphoid cells, neutrophils and some eosinophilic leukocytes, and proliferation of fibroblasts by hematoxylin and eosin (H&E) staining ( Figure 4A-C) . Accordingly, the patient was diagnosed with degree III HFSR. The above symptoms were rapidly alleviated after appropriate symptomatic treatments. 
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Discussion
HFSR is mainly occurred in cancer patients taking antiangiogenic targeted drugs, while HFS is generally caused by fluorouracil, capecitabine, vinorelbine, and other chemotherapeutic agents. 4, 5 HFSR and HFS are both characterized by palmoplantar skin reaction. HFSR is characterized by dry skin around the fingers or toes and erythema, whereas HFS is characterized by symmetrical numbness, erythema, and edema. Previous studies have demonstrated that the anti-tumor effect of patients with HFSR after anti-angiogenic therapy was significantly higher than that of the patients without skin reaction. 6, 7 To date, there has been only one report concerning HFSR in patients with rectal cancer caused by gemcitabine chemotherapy. 8 It should be mentioned that the pathogenesis of HFSR is still unclear. The diagnosis of HFSR is mainly based on the medication history, latency, and remission after dosage reduction or withdrawal. So far, no case of HFSR caused by Act-D chemotherapy, as shown in this study, has been reported. The patient in this study had OCA complicated with invasive submit your manuscript | www.dovepress.com
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Yan et al hydatidiform mole. The related gene mutation caused the melanin deficiency to induce significant changes in the eye and skin. Chemotherapy is required for the treatment of invasive hydatidiform mole. It has been reported that melanin acts as the binding site of some drugs and compounds. 9 Related drugs and compounds must be combined with melanin to play an effective role, showing melanin-related side effects, such as pigmentation. Studies have illustrated OCA2 localizes in pigmented structures in mouse melanocytes that bear markers of mature melanosomes, and melanosomes was required for OCA2 function. 10, 16 Moreover, the study by Cheng et al have shown that UPR attenuation contributes to the extreme chemoresistance phenotype we observed previously in OCA2-null cells. 11 In the reports reviewed in this manuscript, no pigmentation and serious adverse events were experienced during the 5-FU course of chemotherapy, and the patient showed 5-FU resistance. After 2 courses of Act-D chemotherapy, the β-hCG level normalized, and the skin reaction appeared between the 2 courses of Act-D chemotherapy. With subsequent treatment courses, the skin reaction gradually worsened. In the last course of Act-D chemotherapy, the skin burst with pain caused by ulcerative dermatitis at the palmar and metatarsal part of the foot was experienced, which seriously affected daily life and was obviously relieved after drug withdrawal. The patient was diagnosed with degree III HFSR. Gene mutations in OCA patients have been previously observed. 12, 13 In addition, inhibition of melanogenesis can sensitize human melanoma cells toward chemo-, immuno-and radio-therapy. 14, 15 The presented data may suggest a supersensitivity of OCA patients towards Act-D chemotherapy for OCA mutations. However, due to time constraints in this case, the gene mutations were not evaluated by sequencing. Future studies will further explore whether there is a relationship between OCA gene mutation and HFSR caused by chemotherapy.
Conclusion
In the presented case, according to the patient's medical history and clinical features, we speculated that OCA patients are relatively insensitive to 5-FU, which may be due to the absence of melanin caused by OCA2 gene mutation and lack of 5-FU binding sites. Loss of OCA2 also disrupts melanogenesis and increases sensitize to Act-D chemotherapy. Thus, OCA patients might get clinical benefits from protective pharmacologic manipulation during Act-D chemotherapy.
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